Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Lucillia Bezu; Oliver Kepp; Guido Kroemer

doi:10.1080/2162402X.2023.2272352

Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

Lucillia Bezu, Oliver Kepp, Guido Kroemer

Résultats de recherche: Contribution à un journal › Editorial

1 Citation (Scopus)

Résumé

Recent clinical trials have compared the use of different chemotherapeutic regimens as “immune induction therapies” to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.

langue originale	Anglais
Numéro d'article	2272352
journal	OncoImmunology
Volume	12
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2023.2272352
état	Publié - 1 janv. 2023

Accès au document

10.1080/2162402X.2023.2272352

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{fc8f24b3624545a3800c9a91285d7d9b,

title = "Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors",

abstract = "Recent clinical trials have compared the use of different chemotherapeutic regimens as “immune induction therapies” to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.",

keywords = "Cancer, immunogenic cell death, immunotherapy",

author = "Lucillia Bezu and Oliver Kepp and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2023",

month = jan,

day = "1",

doi = "10.1080/2162402X.2023.2272352",

language = "English",

volume = "12",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Immunogenic chemotherapy sensitizes RAS-mutated colorectal cancers to immune checkpoint inhibitors

AU - Bezu, Lucillia

AU - Kepp, Oliver

AU - Kroemer, Guido

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Recent clinical trials have compared the use of different chemotherapeutic regimens as “immune induction therapies” to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.

AB - Recent clinical trials have compared the use of different chemotherapeutic regimens as “immune induction therapies” to sensitize cancers to immune checkpoint inhibitors (ICI). Cytotoxic drugs reputed to be inducers of immunogenic cell death (ICD) appeared to be particularly efficient for this purpose. A trial published in Nature Medicine by Thibaudin et al. reveals the capacity of oxaliplatin-based chemotherapy to sensitize RAS-mutant unresectable metastatic colorectal cancer to ICIs blocking CTLA-4 and PD-L1.

KW - Cancer

KW - immunogenic cell death

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85176216890&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2023.2272352

DO - 10.1080/2162402X.2023.2272352

M3 - Editorial

AN - SCOPUS:85176216890

SN - 2162-4011

VL - 12

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2272352

ER -